# Patrick O`Connor

> Patrick O`Connor is a startup investor. See 0 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Last updated: Oct 2026

Patrick O`Connor is a startup investor. Patrick O’Connor has a long career in the field of oncology drug discovery and development. His contributions include over 100 publications and patents, and over 20 compounds brought successfully into development, including the recently approved anticancer drugs Xalkori (Crizotinib, PF-234,1066) and Inlyta (Axitinib, AG-13736), discovered while atPfizer, where Patrick served as the Global Research Therapeutic Area Head for Oncology. Several additional investigative agents that Patrick helped bring into early clinical development are currently undergoing trials in cancer patients, including PF-136,7338 (PARP, PII, Pfizer/Clovis), PF-344,6962 (Anti-ALK mAb, PI, Pfizer), RDEA119 (MEK, Phase II, Ardea/Bayer), and PEGPH20 (HA, Phase I, Halozyme). Patrick is a Co-Founder of Selexagen Therapeutics that licensed the B-RAF Adaptation Inhibitor Program to Ruga Corporation where he now oversees Oncology activities. He also serves as one of the Senior Editors at the journal Cancer Research and is a member of the Scientific Advisory Boards of Molecular Response and Deciphera Pharmaceuticals. Prior to joining the pharmaceutical industry, Patrick spent 10 years at the National Cancer Institute in Bethesda, Maryland investigating the molecular underpinnings of chemosensitivity. He has a Ph.D. in Experimental Oncology Therapeutics from Manchester University, England.

## Contacts

5 contacts available for Patrick O`Connor: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/patrick-o-connor?utm_source=investor_profile

## FAQ

### How do I contact Patrick O`Connor?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co